Graham Capital Management’s Pacira BioSciences PCRX Stock Holding History

Graham Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,018	Closed	-$224K	–	1538
2025 Q1	$224K	Sell	9,018 -3,250	-26%	-$77.8K	﹤0.01%	1099
2024 Q4	$231K	Sell	12,268 -61,645	-83%	-$1.08M	﹤0.01%	1030
2024 Q3	$1.11M	Buy	+73,913	New	+$1.26M	0.02%	427
2024 Q1	–	Sell	-6,486	Closed	-$219K	–	1242
2023 Q4	$219K	Sell	6,486 -1,555	-19%	-$45.5K	﹤0.01%	817
2023 Q3	$247K	Buy	+8,041	New	+$290K	0.01%	789
2023 Q2	–	Sell	-14,918	Closed	-$609K	–	1226
2023 Q1	$609K	Sell	14,918 -12,741	-46%	-$507K	0.02%	682
2022 Q4	$1.07M	Buy	+27,659	New	+$1.35M	0.03%	505
2022 Q3	–	Sell	-5,446	Closed	-$317K	–	1255
2022 Q2	$317K	Buy	+5,446	New	+$357K	0.01%	811

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Graham Capital Management's PCRX Position: Q2 2025 in Review

Graham Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 9,018 shares — an estimated $224K sold.

Graham Capital Management first reported a position in PCRX in Q2 2022 and held it in 8 quarters. The position peaked at $1.11M in Q3 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

Graham Capital Management reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
Graham Capital Management sold 9,018 Pacira BioSciences shares in Q2 2025, an estimated $224K.
Graham Capital Management first reported a position in Pacira BioSciences in Q2 2022 and held it in 8 quarters.
Graham Capital Management's Pacira BioSciences position peaked at $1.11M in Q3 2024.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.